Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Abstract Background Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-β/PD-L1 bispecific antibody YM101 in immune-excluded tumors. However, Y...

Full description

Bibliographic Details
Main Authors: Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Kongming Wu
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Hematology & Oncology
Subjects:
STING
PD-1
PD-L1
TGF-β
Cancer immunotherapy
Bispecific antibody
Online Access:https://doi.org/10.1186/s13045-022-01363-8

Internet

https://doi.org/10.1186/s13045-022-01363-8

Similar Items